ID   UM-SCC-11B
AC   CVCL_7716
SY   UM-SCC-11b; UM-SCC 11B; UMSCC-11B; UMSCC11B; UM-SCC11B; SCC11B; University of Michigan-Squamous Cell Carcinoma-11B; 11B
DR   BTO; BTO:0005995
DR   cancercelllines; CVCL_7716
DR   Cosmic; 932288
DR   Cosmic; 948028
DR   Cosmic; 1130354
DR   Cosmic; 1317414
DR   Cosmic; 1351517
DR   Cosmic; 2296306
DR   Cosmic; 2131861
DR   Cosmic; 2602597
DR   IARC_TP53; 18876
DR   Wikidata; Q54990808
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RX   PubMed=1851275;
RX   PubMed=1958593;
RX   PubMed=3855324;
RX   PubMed=8679156;
RX   PubMed=9139877;
RX   PubMed=10956384;
RX   PubMed=12884349;
RX   PubMed=15287027;
RX   PubMed=15495191;
RX   PubMed=16785414;
RX   PubMed=17312569;
RX   PubMed=18006756;
RX   PubMed=18487078;
RX   PubMed=19760794;
RX   PubMed=20947470;
RX   PubMed=21868764;
RX   PubMed=23613873;
RX   PubMed=25275298;
RX   PubMed=26045983;
RX   PubMed=26122845;
RX   PubMed=29156801;
RX   PubMed=31541927;
CC   Part of: OPC-22 oral and pharyngeal cancer cell line panel.
CC   Doubling time: 31 +- 3 hours (PubMed=9139877).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15495191; PubMed=18487078; PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gly2569Ser (c.7705G>A); ClinVar=VCV000134697; Zygosity=Heterozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Leu4069Phe (c.12205C>T); ClinVar=VCV001412971; Zygosity=Heterozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Arg912Trp (c.2734C>T); ClinVar=VCV000134921; Zygosity=Homozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Ser (c.725G>C); ClinVar=VCV000647334; Zygosity=Homozygous (PubMed=12884349; PubMed=15287027; PubMed=18006756; PubMed=18487078; PubMed=23613873; PubMed=25275298; PubMed=31541927).
CC   Omics: Deep exome analysis.
CC   Omics: Genome sequenced (low read coverage).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Larynx; UBERON=UBERON_0001737.
ST   Source(s): PubMed=19760794; PubMed=21868764; PubMed=25275298
ST   Amelogenin: X
ST   CSF1PO: 7
ST   D13S317: 14
ST   D16S539: 12,14
ST   D18S51: 16
ST   D21S11: 28
ST   D3S1358: 16
ST   D5S818: 11
ST   D7S820: 11
ST   D8S1179: 15
ST   FGA: 19
ST   Penta D: 2.2
ST   Penta E: 8,13
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 16,17,18
DI   NCIt; C4044; Laryngeal squamous cell carcinoma
DI   ORDO; Orphanet_494550; Squamous cell carcinoma of the larynx
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_7715 ! UM-SCC-11A
SX   Male
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RA   Carey T.E.;
RT   "Head and neck tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York (1994).
//
RX   PubMed=1851275; DOI=10.1177/019459989110400304;
RA   Bradford C.R., Zacks S.E., Androphy E.J., Gregoire L., Lancaster W.D.,
RA   Carey T.E.;
RT   "Human papillomavirus DNA sequences in cell lines derived from head
RT   and neck squamous cell carcinomas.";
RL   Otolaryngol. Head Neck Surg. 104:303-310(1991).
//
RX   PubMed=1958593; DOI=10.1002/gcc.2870030406;
RA   Bradford C.R., Kimmel K.A., Van Dyke D.L., Worsham M.J., Tilley B.J.,
RA   Burk D., del Rosario F., Lutz S., Tooley R., Hayashida D.J.S.,
RA   Carey T.E.;
RT   "11p deletions and breakpoints in squamous cell carcinoma: association
RT   with altered reactivity with the UM-E7 antibody.";
RL   Genes Chromosomes Cancer 3:272-282(1991).
//
RX   PubMed=3855324; DOI=10.1288/00005537-198501000-00012;
RA   Baker S.R.;
RT   "An in vivo model for squamous cell carcinoma of the head and neck.";
RL   Laryngoscope 95:43-56(1985).
//
RX   PubMed=8679156; DOI=10.1007/BF00178278;
RA   Koldovsky P., Haas I., Bier H., Ganzer U.;
RT   "Immunohistochemical examination of 11 cell lines derived from human
RT   head and neck squamous cell carcinomas, their recurrences or
RT   metastases.";
RL   Eur. Arch. Otorhinolaryngol. 252:359-365(1995).
//
RX   PubMed=9139877; DOI=10.1002/(SICI)1097-0215(19970502)71:3<410::AID-IJC18>3.0.CO;2-J;
RA   Welters M.J.P., Fichtinger-Schepman A.M.J., Baan R.A., Hermsen M.A.J.A.,
RA   van der Vijgh W.J.F., Cloos J., Braakhuis B.J.M.;
RT   "Relationship between the parameters cellular differentiation,
RT   doubling time and platinum accumulation and cisplatin sensitivity in a
RT   panel of head and neck cancer cell lines.";
RL   Int. J. Cancer 71:410-415(1997).
//
RX   PubMed=10956384; DOI=10.1002/1097-0215(20000915)87:6<771::AID-IJC2>3.0.CO;2-V;
RA   Backus H.H.J., Pinedo H.M., Wouters D., Padron J.M., Molders N.,
RA   van der Wilt C.L., van Groeningen C.J., Jansen G., Peters G.J.;
RT   "Folate depletion increases sensitivity of solid tumor cell lines to
RT   5-fluorouracil and antifolates.";
RL   Int. J. Cancer 87:771-778(2000).
//
RX   PubMed=12884349; DOI=10.1002/hed.10274;
RA   Bradford C.R., Zhu S.-B., Ogawa H., Ogawa T., Ubell M., Narayan A.,
RA   Johnson G., Wolf G.T., Fisher S.G., Carey T.E.;
RT   "P53 mutation correlates with cisplatin sensitivity in head and neck
RT   squamous cell carcinoma lines.";
RL   Head Neck 25:654-661(2003).
//
RX   PubMed=15287027; DOI=10.1002/gcc.20066;
RA   Takebayashi S., Hickson A., Ogawa T., Jung K.-Y., Mineta H., Ueda Y.,
RA   Grenman R., Fisher S.G., Carey T.E.;
RT   "Loss of chromosome arm 18q with tumor progression in head and neck
RT   squamous cancer.";
RL   Genes Chromosomes Cancer 41:145-154(2004).
//
RX   PubMed=15495191; DOI=10.1002/gcc.20119;
RA   Raschke S., Balz V., Efferth T., Schulz W.A., Florl A.R.;
RT   "Homozygous deletions of CDKN2A caused by alternative mechanisms in
RT   various human cancer cell lines.";
RL   Genes Chromosomes Cancer 42:58-67(2005).
//
RX   PubMed=16785414; DOI=10.1001/archotol.132.6.668;
RA   Worsham M.J., Chen K.M., Meduri V., Nygren A.O.H., Errami A.,
RA   Schouten J.P., Benninger M.S.;
RT   "Epigenetic events of disease progression in head and neck squamous
RT   cell carcinoma.";
RL   Arch. Otolaryngol. Head Neck Surg. 132:668-677(2006).
//
RX   PubMed=17312569; DOI=10.1002/hed.20478;
RA   Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L.,
RA   Koch W.M., Ferris R.L., Lai S.Y.;
RT   "Head and neck squamous cell carcinoma cell lines: established models
RT   and rationale for selection.";
RL   Head Neck 29:163-188(2007).
//
RX   PubMed=18006756; DOI=10.1158/1078-0432.CCR-07-1591;
RA   Friedman J., Nottingham L., Duggal P., Pernas F.G., Yan B., Yang X.-P.,
RA   Chen Z., Van Waes C.;
RT   "Deficient TP53 expression, function, and cisplatin sensitivity are
RT   restored by quinacrine in head and neck cancer.";
RL   Clin. Cancer Res. 13:6568-6578(2007).
//
RX   PubMed=18487078; DOI=10.1016/j.oraloncology.2008.02.006;
RA   Hoffmann T.K., Sonkoly E., Hauser U., van Lierop A., Whiteside T.L.,
RA   Klussmann J.P., Hafner D., Schuler P.J., Friebe-Hoffmann U.,
RA   Scheckenbach K., Erjala K., Grenman R., Schipper J., Bier H.,
RA   Balz V.;
RT   "Alterations in the p53 pathway and their association with radio- and
RT   chemosensitivity in head and neck squamous cell carcinoma.";
RL   Oral Oncol. 44:1100-1109(2008).
//
RX   PubMed=19760794; DOI=10.1002/hed.21198;
RA   Brenner J.C., Graham M.P., Kumar B., Saunders L.M., Kupfer R.,
RA   Lyons R.H., Bradford C.R., Carey T.E.;
RT   "Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell
RT   lines.";
RL   Head Neck 32:417-426(2010).
//
RX   PubMed=20947470; DOI=10.1186/2047-783X-15-8-337;
RA   Schuler P.J., Trellakis S., Greve J., Bas M.B., Bergmann C., Bolke E.,
RA   Lehnerdt G.F., Mattheis S., Albers A.E., Brandau S., Lang S.K.,
RA   Whiteside T.L., Bier H., Hoffmann T.K.;
RT   "In vitro chemosensitivity of head and neck cancer cell lines.";
RL   Eur. J. Med. Res. 15:337-344(2010).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=23613873; DOI=10.1371/journal.pone.0061555;
RA   Martens-de Kemp S.R., Dalm S.U., Wijnolts F.M.J., Brink A.,
RA   Honeywell R.J., Peters G.J., Braakhuis B.J.M., Brakenhoff R.H.;
RT   "DNA-bound platinum is the major determinant of cisplatin sensitivity
RT   in head and neck squamous carcinoma cells.";
RL   PLoS ONE 8:E61555-E61555(2013).
//
RX   PubMed=25275298; DOI=10.18632/oncotarget.2417;
RA   Martin D., Abba M.C., Molinolo A.A., Vitale-Cross L., Wang Z.-Y.,
RA   Zaida M., Delic N.C., Samuels Y., Lyons J.G., Gutkind J.S.;
RT   "The head and neck cancer cell oncogenome: a platform for the
RT   development of precision molecular therapies.";
RL   Oncotarget 5:8906-8923(2014).
//
RX   PubMed=26045983;
RA   Ziemann F., Arenz A., Preising S., Wittekindt C., Klussmann J.P.,
RA   Engenhart-Cabillic R., Wittig A.;
RT   "Increased sensitivity of HPV-positive head and neck cancer cell lines
RT   to X-irradiation +/- cisplatin due to decreased expression of E6 and
RT   E7 oncoproteins and enhanced apoptosis.";
RL   Am. J. Cancer Res. 5:1017-1031(2015).
//
RX   PubMed=26122845; DOI=10.1158/0008-5472.CAN-15-0528;
RA   Stoepker C., Ameziane N., van der Lelij P., Kooi I.E., Oostra A.B.,
RA   Rooimans M.A., van Mil S.E., Brink A., Dietrich R., Balk J.A.,
RA   Ylstra B., Joenje H., Feller S.M., Brakenhoff R.H.;
RT   "Defects in the Fanconi anemia pathway and chromatid cohesion in head
RT   and neck cancer.";
RL   Cancer Res. 75:3543-3553(2015).
//
RX   PubMed=29156801; DOI=10.18632/oncotarget.21174;
RA   Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y.,
RA   Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J.,
RA   Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.;
RT   "Genomic characterization of human papillomavirus-positive and
RT   -negative human squamous cell cancer cell lines.";
RL   Oncotarget 8:86369-86383(2017).
//
RX   PubMed=31541927; DOI=10.1016/j.oraloncology.2019.09.004;
RA   van Harten A.M., Poell J.B., Buijze M., Brink A., Wells S.I.,
RA   Leemans C.R., Wolthuis R.M.F., Brakenhoff R.H.;
RT   "Characterization of a head and neck cancer-derived cell line panel
RT   confirms the distinct TP53-proficient copy number-silent subclass.";
RL   Oral Oncol. 98:53-61(2019).
//